99m Tc-MDP 骨显像诊断肾性骨病的临床意义.pdf

文档介绍：012 LabeledImmunoassays&ClinMed,,,
446. engineeredantibodiesspecificfortheMullerianinhibitingsubstance
[28]BenderNK,HeiligCE,DrollB,,efficacy typeIIreceptor:apromisingcandidatefortargetedtherapyofovari
andadverseeventsofadalimumabinRApatients[J].Rheumatol ancancer[J].MolCancerTher,2006,5(8):20962105.
Int,2007,27(3):269274. [33]MondonP,DubreuilO,BouayadiK,
[29]ZhouH,JangH,FleischmannRM, ies:aracetoengineerandexplorealargerdiversity[J].FrontBio
safetyofgolimumab,afullyhumanantiTNFalphamonoclonalanti sci,2008,13:11171129.
body,insubjectswithrheumatoidarthritis[J].JClinPharmacol, [34]HoetRM,CohenEH,KentRB,affinity
2007,47(3):383396. biningdonorple
[30]LiS,KussieP, mentaritydeterminingregiondiversity[J].JNatBiotechnol,2005,
inhibitionbythetherapeuticantibodyIMC11F8[J].Structure, 23(3):334348.
2008,16(2):216227. [35]HoM,KreitmanRJ,OndaM,
[31]JosteckT,, targetinggermlinehotspotstoIncreaseactivityofanantiCD22im
tionalhumanIgGantibodiesderivedfromFabonphagedisplayli munotoxin[J].JBidChem,2005,280(1):607617.
braries[J].ImmunolMethod,2004,289(12):6580. (刘晓敏编辑)
[32]YuanQA,SimmonsHH,RobinsonM K,
99m TcMDP骨显像诊断肾性骨病的临床